Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.

Scientific reports - 20 Feb 2020

Yasutake Yoshiaki, Hattori Shin-Ichiro, Tamura Noriko, Matsuda Kouki, Kohgo Satoru, Maeda Kenji, Mitsuya Hiroaki

Abstract excerpt

Chronic hepatitis B virus (HBV) infection is a major public health problem that affects millions of people worldwide. Nucleoside analogue reverse transcriptase (RT) inhibitors, such as entecavir (ETV) and lamivudine (3TC), serve as crucial anti-HBV drugs. However, structural studies of HBV RT have been hampered due to its unexpectedly poor solubility. Here, we show that human immunodeficiency virus type-1 (HIV-1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxyguanine Nucleotides
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Lamivudine

Share to Nucleic Acid Conformation

Share to Nucleosides

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Source

Open in PubMed Open full text

Identifiers

PMID: 32080249
DOI: 10.1038/s41598-020-59775-w
PMCID: PMC7033138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.PMID 32080249Read ↗

Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.Semantic proximity Read ↗

Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.Semantic proximity Read ↗

Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.Semantic proximity Read ↗

Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.Semantic proximity Read ↗

Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.Semantic proximity Read ↗

Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.Semantic proximity Read ↗

Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.Semantic proximity Read ↗

Understanding the Genetics of Viral Drug Resistance by Integrating Clinical Data and Mining of the Scientific LiteratureSemantic proximity Read ↗

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

Understanding the molecular basis of HBV drug resistance by molecular modeling.Semantic proximity Read ↗

Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature.Semantic proximity Read ↗

Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.